Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human randomized placebo-controlled study of ARGX-117 in healthy volunteers
NL-OMON52853Phase 1Completed
- Sponsor
- argenx
- Start
- Mar 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of empasiprubart in complement-associated pathology and autoimmune disease (14 arms), sponsored by argenx. Started Mar 2020; status: completed.
02
Drugs
empasiprubart
03
Conditions
complement-associated pathologyautoimmune disease
Beyond the preview
Go deeper on NL-OMON52853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52853.